Answers are grounded in this paper and cite their sources.
Giant cell arteritis (GCA) is a systemic rheumatic disease that affects the large vessels. Although ischemic stroke is an uncommon complication of GCA, intracranial vasculitis may lead to recurrent strokes. An 81-year-old man presented with progressive gait disturbance. Physical examination revealed bilateral temporal artery tenderness with markedly diminished pulsation. His serum C-reactive protein level was elevated. Temporal artery ultrasonography demonstrated bilateral halo signs. Brain magnetic resonance imaging revealed multiple acute strokes. Vessel wall imaging demonstrated circumferential wall thickening with contrast enhancement of the bilateral intracranial internal carotid and vertebral arteries. He fulfilled the 2022 ACR/EULAR classification criteria for GCA. Treatment with intravenous methylprednisolone followed by high-dose glucocorticoid (GC) and weekly subcutaneous (SC) tocilizumab (TCZ) was initiated. However, recurrent ischemic strokes occurred early after treatment initiation, accompanied by progression of intracranial arterial stenosis. Therefore, TCZ was subsequently switched to upadacitinib (UPA) 15 mg/day. Following the switch to UPA, the serum C-reactive protein level normalized, no further ischemic strokes occurred, and follow-up contrast-enhanced MRI demonstrated resolution of vascular wall enhancement. This case describes clinical and radiological improvement observed following the switch to UPA in rapidly progressive GCA with intracranial involvement.
No takes yet. Share an insight, caveat, or question.
Yonezawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: